
Heska Corporation HSKA
Quarterly report 2023-Q1
added 05-05-2023
Heska Corporation Interest Expense 2011-2026 | HSKA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.19 M | 4.2 M | 6.37 M | 3.09 M | 310 K | 245 K | 160 K | 200 K | 206 K | 74 K | 117 K | 124 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.37 M | 74 K | 1.61 M |
Quarterly Interest Expense Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 939 K | - | 1.17 M | 931 K | 925 K | - | 918 K | 922 K | 920 K | - | 2.34 M | 2.33 M | 2.35 M | - | 494 K | 147 K | 77 K | - | 89 K | 77 K | 65 K | - | 81 K | 51 K | 24 K | - | 54 K | 38 K | 38 K | - | 51 K | 50 K | 52 K | - | 48 K | 52 K | 50 K | - | 82 K | 90 K | 57 K | - | 29 K | 29 K | 30 K | - | 69 K | 22 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.35 M | 22 K | 436 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
81 M | $ 115.62 | 0.06 % | $ 35.1 B | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
106 K | $ 1.65 | -1.2 % | $ 2.19 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
1 K | $ 24.98 | 2.13 % | $ 694 M | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
CareDx, Inc
CDNA
|
524 K | $ 21.85 | 2.92 % | $ 1.16 B | ||
|
Illumina
ILMN
|
-292 M | $ 128.52 | 0.5 % | $ 20.4 B | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 15.6 | -4.35 % | $ 472 M | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 84.11 | -0.26 % | $ 5.68 B | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 171.23 | 0.86 % | $ 8.49 B | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 421.37 | 2.64 % | $ 12.2 B | ||
|
Guardant Health
GH
|
-10.5 M | $ 88.5 | -0.46 % | $ 11.1 B | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.54 | 0.25 % | $ 20 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Personalis
PSNL
|
24 K | $ 5.96 | -2.3 % | $ 353 M | ||
|
Interpace Biosciences
IDXG
|
-252 K | $ 1.93 | -2.08 % | $ 8.54 M | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 7.27 | 3.12 % | $ 303 M | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | ||
|
Soleno Therapeutics
SLNO
|
110 K | $ 52.75 | 0.06 % | $ 2.68 B | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 9.45 | -0.94 % | $ 2.05 B | ||
|
Biomerica
BMRA
|
367 | $ 2.18 | 1.87 % | $ 5.01 M | ||
|
National Research Corporation
NRC
|
-95 K | $ 17.11 | -0.7 % | $ 383 M | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 468.04 | -0.36 % | $ 176 B | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 103.21 | 1.02 % | $ 8.51 B | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 263.43 | -0.12 % | $ 21.9 B | ||
|
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.64 | -0.82 % | $ 61.9 M | ||
|
Celcuity
CELC
|
2.11 M | $ 125.68 | 3.84 % | $ 5.88 B | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 61.0 | 0.1 % | $ 3.65 B | ||
|
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
296 K | $ 8.61 | 3.86 % | $ 1.1 B | ||
|
Myriad Genetics
MYGN
|
800 K | $ 4.83 | 1.05 % | $ 447 M | ||
|
Natera
NTRA
|
9.32 M | $ 204.39 | 0.31 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
26 M | $ 196.63 | 0.21 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M |